Economic Burden of Respiratory Viruses in Latin America and the Caribbean (LAC): A Scoping Literature Review
Influenza and Other Respiratory Viruses · 2025-09 · 19 (9)
DOI: 10.1111/irv.70148 ↗Kurz gefasst
Scoping Review in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 04.09.2025. Verfasst von Nelson J Alvis-Zakzuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pan-American Health Organization, Washington, DC, USA. Hauptthemen laut MEDLINE: Cost of Illness, COVID-19, Respiratory Tract Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Objective
The objective of this study is to summarize the state of knowledge on the economic burden and cost of illness due to influenza, SARS‐CoV‐2, respiratory syncytial virus (RSV), and other respiratory viruses (ORV) in Latin America and the Caribbean (LAC).
Methods
We performed a scoping review across three databases (PubMed‐Medline, Scielo, and Embase) without time restriction, including economic burden and cost‐of‐illness studies. We extracted and analyzed data on publication year, population, study type, perspective, costing techniques, and settings. We reported absolute and relative frequencies to summarize the results. Economic burden estimates were divided by the gross domestic product (GDP) for each country. Costs were converted into 2022 international dollars (PPP).
Results
Overall, 2638 articles were retrieved; we included 44 full texts from 16 LAC countries. Twenty‐four (54.5%) studies focused on influenza, 16 (36.4%) on SARS‐CoV‐2, 3 (6.8%) on RSV, and 1 on ORV. Twenty two (50.0%) focused on cost‐effectiveness (related to vaccination)/cost–benefit analysis, and 17 (38.6%) focused on cost of illness. Most studies ( n = 33, 75.0%) were conducted from the third‐party perspective. Fifty percent of the studies used a bottom‐up costing technique and 29.6% top‐down. Influenza direct medical costs ranged from I$6.6–I$300.3 for outpatients and I$62.8–I$222,920 for inpatients; for RSV from I$68.3–I$1292; and for SARS‐CoV‐2 between I$69.9 and I$38,039. The total annual costs of the influenza economic burden ranged between 0.0003% and 1.33% of the GDP.
Conclusion
This study showed variability in costing methods, perspectives, and types of studies among LAC countries. This variability underscores the need for standardized methodologies in future cost studies to ensure comparability and reliability of results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pan-American Health Organization, Washington, DC, USA.
- Partnership for International Vaccine Initiative, Taskforce for Global Health, Atlanta, Georgia, USA.
ORCID-Profile: Nelson J Alvis-Zakzuk, Stefano Tempia
Förderung
- World Health Organization
Zitieren
APA
Alvis-Zakzuk, N. J., Couto, P., Jara, J. H., Descalzo, M., Rondy, M., Tempia, S., & Vicari, A. (2025). Economic Burden of Respiratory Viruses in Latin America and the Caribbean (LAC): A Scoping Literature Review. Influenza and Other Respiratory Viruses, 19(9). https://doi.org/10.1111/irv.70148
Vancouver
Alvis-Zakzuk NJ, Couto P, Jara JH, Descalzo M, Rondy M, Tempia S, et al. Economic Burden of Respiratory Viruses in Latin America and the Caribbean (LAC): A Scoping Literature Review. Influenza and Other Respiratory Viruses. 2025;19(9). doi:10.1111/irv.70148
BibTeX
@article{AlvisZakzuk2025,
author = {Alvis-Zakzuk, Nelson J and Couto, Paula and Jara, Jorge H and Descalzo, Miguel and Rondy, Marc and Tempia, Stefano and Vicari, Andrea},
title = {Economic Burden of Respiratory Viruses in Latin America and the Caribbean (LAC): A Scoping Literature Review},
journal = {Influenza and Other Respiratory Viruses},
year = {2025},
volume = {19},
number = {9},
doi = {10.1111/irv.70148}
}
EUVIMED